RVMD logo

Revolution Medicines Inc - Ordinary Shares (RVMD)

$149.23

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RVMD

Market cap

$31.73B

EPS

-7.11

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.406951

Price on RVMD

Previous close

$155.69

Today's open

$153.67

Day's range

$148.15 - $154.97

52 week range

$34 - $166.50

Profile about RVMD

CEO

Mark A. Goldsmith

Employees

534

Headquarters

Redwood City, CA

Exchange

Nasdaq Global Select

Shares outstanding

212596462

Issue type

Common Stock

RVMD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RVMD

Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Jun 5, 2026

news preview

Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

news source

Seeking Alpha • Jun 1, 2026

news preview

RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study

Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.

news source

Zacks Investment Research • Jun 1, 2026

news preview

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients ​live 15% longer than BeOne Medicines' Tevimbra immunotherapy.

news source

Reuters • Jun 1, 2026

news preview

Revolution's pancreatic cancer drug doubles survival, boosts quality of life

Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients could resume ​activities they had previously abandoned, setting a new benchmark for this deadly cancer, researchers reported on Sunday.

news source

Reuters • May 31, 2026

news preview

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine

news source

GlobeNewsWire • May 31, 2026

news preview

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

news source

GlobeNewsWire • May 21, 2026

news preview

GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and biotech.

news source

Benzinga • May 19, 2026

news preview

Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease.

news source

Benzinga • May 15, 2026

news preview

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from ​Revolution Medicines while they await what they hope will be a speedy FDA approval.

news source

Reuters • May 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Revolution Medicines Inc - Ordinary Shares

Open an M1 investment account to buy and sell Revolution Medicines Inc - Ordinary Shares commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RVMD on M1